


Amendments to the Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1. (Currently Amended) A compound of formula I,



wherein

R₁ and R₂ are independently hydrogen, halo, or lower alkyl, heterocycle, amine or cycloalkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-amino-lower alkyl, heterocycle-lower alkyl; or R₁ and R₂ can join together to form a N-heterocycle or lower alkyl-N-heterocycle all of which may be unsubstituted or substituted;

~~or R₁ and R₂ can join together to form an unsubstituted or substituted N-heterocycle;~~

Y is (R₃)_n-X- or A(R₃)(R₃)C-

wherein

X is lower alkylene, amine, amide or carbonyl;

A is hydroxy, amine, halo, or lower alkyl;

R₃ is lower alkyl, lower alkoxy, carbonyl, amino, hydroxy, heterocycle-heterocyclic, or heteroaryl, lower alkyl-heterocycle, heterocycle-lower alkyl, lower alkyl-amino-lower alkyl, heterocycle-lower alkyl-amino, lower alkyl-amino, hydroxy-lower alkyl-amino, amino substituted by lower alkoxy-lower alkyl and lower alkyl; all of which can be unsubstituted or substituted;

n is 1 or 2;

~~the substituents on R₃ are one or more substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, amino, hydroxy and heterocycle; all of which, except halo, are unsubstituted or substituted by one or more substituents independently selected from the group consisting of halo, hydroxy, lower alkoxy, amino, lower alkyl and heterocycle; all of which, except halo, are unsubstituted or substituted by one or more substituents independently selected~~

from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy and lower alkoxy; the substituents on R_1 and R_2 are one or more substituents independently selected from the group consisting of halo, hydroxy, lower alkyl, lower alkoxy, amino, cycloalkyl, heterocycle and heteroaryl; all of which, except halo, are unsubstituted or substituted by one or more substituents independently selected from the group consisting of halo, hydroxy, lower alkyl, lower alkoxy, amino, heterocycle and heteroaryl; all of which, except halo, are unsubstituted or substituted by one or more substituents independently selected from the group consisting of halo, hydroxy, lower alkyl and amino; wherein heterocyclic is selected from pyrrolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, piperidinyl, pyranyl, pyrazolidinyl, oxiranyl, dioxanyl, imidazolinyl, imidazolidinyl, morpholinoyl and piperazinyl; cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; N-heterocyclic is selected from pyrrolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, morpholinoyl, and piperazinyl; heteroaryl is selected from pyridyl, indanyl, indolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl, benzopyranyl, benzothiopyranyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl and thienyl; or a pharmaceutically acceptable salt, ester thereof.

2.-3. (Cancelled)

4. (Currently Amended) A compound of formula I according to claim 1

R_1 and R_2 are independently hydrogen, methyl, ethyl, propyl, cyclopropyl, hydroxy-propyl, dimethylamino-ethyl, morpholinyl-propyl, methoxy-ethyl, pyrrolidinyl-propyl; or R_1 and R_2 can join together to form a piperazinyl or methyl-piperazinyl, preferably N-methyl-piperazinyl;

Y is $(R_3)_nX-$ or $A(R_3)(R_3)C-$;

wherein

X is CH_2 or $-C(O)-$;

A is hydroxy;

n is 1;

R_3 is methylene, ethylene, butoxy, morpholinyl, piperazinyl, pyrrolyl, tetrazolyl, imidazolyl, methyl-piperazinyl, diethyl-amino-propyl, morpholino-propyl-amino, methyl-amino, hydroxy-propyl-amino,

(methoxy-ethyl)methyl-amino;
or a pharmaceutically acceptable salt or ester thereof.

5. (Currently Amended) A compound of formula I according to claim 1 selected from the group consisting of

methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-propylamine;
[4-(4-methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-morpholin-4-yl-methanone;
[4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-[4-methyl-piperazin-1-yl]-methanone;
dimethyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
N-(3-diethylamino-propyl)-4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzamide;
[4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-morpholin-4-yl-methanone;
4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-N-(3-morpholin-4-yl-propyl)-benzamide;
(4-methyl-piperazin-1-yl)-{4-[4-(4-methyl-piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-
methanone;
4-(4-methyl-piperazin-1-yl)-6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidine;
{4-[4-(ethyl-methyl-amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-(4-methyl-piperazin-1-yl)-
methanone;
[4-(4-isopropylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-(4-methyl-piperazin-1-yl)-methanone;
[4-(4-methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-[4-methyl-piperazin-1-yl]-methanone;
isopropyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
ethyl-methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
{4-[4-(3-hydroxy-propylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-(4-methyl-piperazin-1-yl)-
methanone;
methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
(4-Methyl-piperazin-1-yl)-[4-(4-propylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-methanone;
{6-[4-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-propyl-amine;
~~methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-propyl-amine;~~
{4-(4-Cyclopropylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl}-(4-methyl-piperazin-1-yl)-
methanone;
N-methyl-4-(4-methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzamide;
{4-[4-(2-Dimethylamino-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-(4-methyl-piperazin-1-
yl)-methanone;
N,N-dimethyl-N'-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-
ethane-1,2-diamine;

[6-(4-Imidazol-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-dimethyl-amine;
dimethyl-[6-[4-(1H-pyrrol-2-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine;
[6-(4-Butoxymethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-dimethyl-amine;
dimethyl-[6-(4-tetrazol-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine;
3-[4-(4-Dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzylamino]-propan-1-ol;
[6-(4-[(2-Methoxy-ethyl)-methyl-amino]-methyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-dimethyl-amine;
3-[4-[4-(3-Morpholin-4-yl-propylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl]-pentan-3-ol;
2-(4-[4-[Bis-(2-methoxy-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl)-propan-2-ol;
3-(4-[4-[Bis-(2-methoxy-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl)-pentan-3-ol;
3-[4-[4-(3-Pyrrol-1-yl-propylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl]-pentan-3-ol;
2-[4-(4-Dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-propan-2-ol;
2-[4-(4-Methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-propan-2-ol;
or a pharmaceutically acceptable salt thereof.

6. (Original) A compound of formula I according to claim 1 selected from the group consisting of
[4-(4-methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-morpholin-4-yl-methanone;
[4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-morpholin-4-yl-methanone;
[4-[4-(ethyl-methyl-amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl]-(4-methyl-piperazin-1-yl)-methanone;
isopropyl-[6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine;
ethyl-methyl-[6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine;
methyl-[6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine;
[6-(4-Imidazol-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-dimethyl-amine;
2-[4-(4-Dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-propan-2-ol;
or a pharmaceutically acceptable salt thereof.

7. (Currently Amended) A compound of formula I, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 for use in a method for the treatment of the human or animal body.

8. (Currently Amended) A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 together with at least one pharmaceutically acceptable carrier.

9. (Currently Amended) ~~aA~~ compound of formula I according to ~~any one of claims~~ 1 or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.

10.-13. (Cancelled)

14. (Withdrawn) All novel compounds, methods, processes and uses substantially as hereinbefore described with particular reference to the examples.